Healthcare / BiotechnologyShanghai
$41.00
+1.26 (+3.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-276.6M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.9%
↓Gross Margin
98.6%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+131.5%
FCF CAGR
—
FCF margin
-936.8%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.5M · net income $-137.3M · FCF $-191.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.5M | $20.5M | $366836.28 | — | $1.7M |
| Net Income | $-137.3M | $-137.3M | $-199.5M | $-294.2M | $-301.5M |
| EBITDA | $-129.6M | $-129.6M | $-193.0M | $-286.2M | $-292.1M |
| EPS | -1.39 | -1.39 | -2.01 | -2.97 | -3.32 |
| Gross Margin | 98.6% | 98.6% | 8.4% | — | 53.6% |
| Operating Margin | -768.7% | -768.7% | -60789.3% | — | -20456.7% |
| Net Margin | -670.5% | -670.5% | -54382.8% | — | -18264.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 7.04 | 7.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-191.8M | $-191.8M | $-276.6M | $-354.7M | $-384.1M |
| Returns | |||||
| ROE | -12.9% | -12.9% | -16.7% | -21.5% | -19.0% |
| Valuation | |||||
| P/B | 3.81 | 3.81 | 2.39 | 3.66 | 2.54 |
| Growth & Yield | |||||
| Revenue Growth | 5480.1% | 5480.1% | — | — | — |
| EPS Growth | 30.8% | 30.8% | 32.3% | 10.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.01 → -1.39
Residual
-16.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.